Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2066805rdf:typepubmed:Citationlld:pubmed
pubmed-article:2066805lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0021031lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0303611lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0007974lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0011953lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C2347885lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C1690540lld:lifeskim
pubmed-article:2066805lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:2066805pubmed:issue7lld:pubmed
pubmed-article:2066805pubmed:dateCreated1991-8-9lld:pubmed
pubmed-article:2066805pubmed:abstractTextA kit has been developed for 99mTc antibody radiolabeling via defined chemistry using an N2S2 diamide dimercaptide bifunctional chelating agent and the performed chelate method. The process involved efficient transchelation of 99mTc from gluconate to 2,3,5,6-tetrafluorophenyl 4,5-bis-S-(1-ethoxyethyl) mercaptoacetamidopentanoate as an active ester ligand and subsequent conjugation to antibody lysine amine functional groups. The use of the ethoxyethyl group for sulfur protection allowed optimum yields of 99mTc N2S2 chelate formation with complete retention of the active ester. Subsequent addition of antibody Fab fragment gave 99mTc chelate conjugates indistinguishable from the stepwise in situ esterification and purification of the 99mTc N2S2 complex followed by conjugation as previously shown to give stable 99mTc antibody fragments with retained immunoreactivity and tumor-targeting properties.lld:pubmed
pubmed-article:2066805pubmed:languageenglld:pubmed
pubmed-article:2066805pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:citationSubsetIMlld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2066805pubmed:statusMEDLINElld:pubmed
pubmed-article:2066805pubmed:monthJullld:pubmed
pubmed-article:2066805pubmed:issn0161-5505lld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:RenoJ MJMlld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:SenS KSKlld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:SrinivasanAAlld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:FritzbergA...lld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:KasinaSSlld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:BeaumierP LPLlld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:SandersonJ...lld:pubmed
pubmed-article:2066805pubmed:authorpubmed-author:FitznerJ NJNlld:pubmed
pubmed-article:2066805pubmed:issnTypePrintlld:pubmed
pubmed-article:2066805pubmed:volume32lld:pubmed
pubmed-article:2066805pubmed:ownerNLMlld:pubmed
pubmed-article:2066805pubmed:authorsCompleteYlld:pubmed
pubmed-article:2066805pubmed:pagination1445-51lld:pubmed
pubmed-article:2066805pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:meshHeadingpubmed-meshheading:2066805-...lld:pubmed
pubmed-article:2066805pubmed:year1991lld:pubmed
pubmed-article:2066805pubmed:articleTitleDevelopment and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent.lld:pubmed
pubmed-article:2066805pubmed:affiliationNeoRx Corporation, Seattle, Washington 98119.lld:pubmed
pubmed-article:2066805pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2066805lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2066805lld:pubmed